Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NANot yet recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

September 1, 2026

Conditions
COVID -19Influenza AInfluenza BRespiratory Synctial VirusRSVRhinovirus
Interventions
DIAGNOSTIC_TEST

Aptitude Medical Systems Respiratory Panel Test

The Metrix Respiratory Panel Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus gene targets will produce a positive result, differentiated by each target. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.

Trial Locations (1)

35235

AFC Trussville, Trussville

Sponsors
All Listed Sponsors
lead

Aptitude Medical Systems

INDUSTRY

NCT07217639 - Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings | Biotech Hunter | Biotech Hunter